New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment

Media coverage

• Title	New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment
  Media name/outlet	Bayer HealthCare Pharmaceuticals
  Country/Territory	Germany
  Date	6/11/23
  URL	ct.moreover.com/?a=52258287513&p=1gw&v=1&x=ngblXeZ8tmSp55j-fX943A
  Persons	Roxana Mehran,

• Title	Bayer : New asundexian Phase III study to include patients with atrial fibrillation ineligible for oral anticoagulant treatment
  Media name/outlet	MarketScreener.com
  Country/Territory	United States
  Date	6/11/23
  URL	ct.moreover.com/?a=52257727997&p=1gw&v=1&x=3R0CMcxH9CPmAFI-XqM9Vg
  Persons	Roxana Mehran,